Bristol-Myers hepatitis B drug patent ruled invalid by appeals court
An appeals court affirmed a district court's ruling that Bristol-Myers' (BMY) hepatitis B drug patent is invalid. Teva (TEVA) won the appeal.
Advertisement
Recommended Stories
Walmart CEO started his career unloading trailers at the warehouse—he says he got promotion after promotion by raising his hand when his boss was out of town
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Fortune•Trump to set interest rates himself under secret presidential plan
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The Telegraph•Housing supply surges by up to 50% in these metro areas — and many sellers are being forced to slash their asking prices
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
MarketWatch•2 Stock-Split Stocks to Buy Hand Over Fist Right Now
These proven wealth builders could be exactly what you're searching for right now.
Motley Fool•‘Americans just work harder’ than Europeans, says CEO of Norway’s $1.6 trillion oil fund, because they have a higher ‘general level of ambition’
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
Fortune•1 Unstoppable Stock That Could Join Microsoft, Apple, Nvidia, Alphabet, Amazon, and Meta in the $1 Trillion Club
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Motley Fool•U.S. panic over national debt might mark a culture shift—are Americans becoming more ‘European’ about money?
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Fortune•Holding 10,000 Dogecoin Could Make You A Millionaire, Predicts Crypto Analyst
Since 2021, Dogecoin (DOGE) has consistently been one of the largest cryptocurrencies in the market. The token has attracted tens of billions in investment and is up more than 27,000% since its launch. While the price has fallen considerably since highs, the token has held its own and performed well in 2024. Some do not see the growth stopping anytime soon. According to some analysts, DOGE could reach — and even surpass — the $100 mark. Don't Miss: Dogecoin millionaires are increasing — investor
Benzinga•If I Had to Construct a Portfolio of Just 5 ETFs, Here's Exactly What I'd Buy Right Now
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Motley Fool•A $100,000 salary no longer buys you a middle-class lifestyle. Here’s why it costs so much more now.
“We’re definitely not doing what you would think somebody with our income could do with the money,” one six-figure earner said.
MarketWatch•